Passage Bio, Inc. (PASG)
4.52
+0.19
(+4.39%)
USD |
NASDAQ |
Aug 28, 16:00
4.57
+0.05
(+1.11%)
After-Hours: 20:00
Passage Bio Cash from Operations (Quarterly) : -9.181M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.181M |
| March 31, 2026 | -12.99M |
| December 31, 2025 | -6.479M |
| September 30, 2025 | -4.853M |
| June 30, 2025 | -6.33M |
| March 31, 2025 | -13.85M |
| December 31, 2024 | -8.444M |
| September 30, 2024 | -7.447M |
| June 30, 2024 | -13.14M |
| March 31, 2024 | -18.93M |
| December 31, 2023 | -19.52M |
| September 30, 2023 | -19.16M |
| June 30, 2023 | -17.14M |
| March 31, 2023 | -22.45M |
| December 31, 2022 | -24.02M |
| Date | Value |
|---|---|
| September 30, 2022 | -23.40M |
| June 30, 2022 | -26.08M |
| March 31, 2022 | -44.71M |
| December 31, 2021 | -30.78M |
| September 30, 2021 | -41.06M |
| June 30, 2021 | -24.33M |
| March 31, 2021 | -30.72M |
| December 31, 2020 | -29.42M |
| September 30, 2020 | -17.53M |
| June 30, 2020 | -11.72M |
| March 31, 2020 | -21.85M |
| December 31, 2019 | -16.97M |
| September 30, 2019 | -11.93M |
| June 30, 2019 | -10.78M |
| March 31, 2019 | -0.214M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | -60.93M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -33.50M |
| Free Cash Flow Per Share (Quarterly) | -2.861 |
| Free Cash Flow to Equity (Quarterly) | -3.426M |
| Free Cash Flow to Firm (Quarterly) | -9.181M |
| Free Cash Flow Yield | -232.0% |